Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Azeliragon e quimiorradioterapia em glioblastoma recém-diagnosticado

16 de outubro de 2026 atualizado por: Cantex Pharmaceuticals

Um estudo aberto de Fase I/II para avaliar a segurança e evidências preliminares de um efeito terapêutico de azeliragon combinado com radiação concomitante convencional e temozolomida em pacientes com glioblastoma recém-diagnosticado

This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients with newly diagnosed glioblastoma receiving concurrent radiation and temozolomide.

Visão geral do estudo

Descrição detalhada

Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.

Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.

Patients will be accrued in groups of six starting with Dose Level 1. Escalation will continue as described in Table 2 until stopping rules are met or the highest defined dose level is reached. If Dose Level 1 is deemed intolerable, the trial will be closed to accrual.

The dose limiting toxicities (DLT) evaluation period will be defined as 28 days from initiation of dosing. The severity of adverse events will be graded according to CTCAE v 5.0. For the purpose of dose-finding, any listed AEs occurring during the DLT period, which are attributable (definite, probable, possible) to azeliragon will be classified as a DLT. In addition, the RP2/3D will take into account dose-reductions, treatment interruptions, discontinuation, and toxicities after the DLT period.

RP2/3D was defined as the dose with 6 patients treated at that dose level with ≤ 1 DLT observed.

Tipo de estudo

Intervencional

Inscrição (Real)

33

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Barcelona
      • Barcelona, Barcelona, Espanha, 08003
        • Hospital del Mar
      • Barcelona, Barcelona, Espanha, 08036
        • Hospital Clínic de Barcelona
    • Madrid
      • Madrid, Madrid, Espanha, 28041
        • Hospital Universitario 12 de Octubre
      • Madrid, Madrid, Espanha, 28034
        • Hospital Universitario Ramon y Cajal

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 70 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Patient must have histologically confirmed newly diagnosed glioblastoma (GBM, world health organization (WHO) grade IV). The histological diagnosis must have been made after biopsy or neurosurgical tumor resection.

    Note: Patients should be isocitrate dehydrogenase (IDH) wild type diagnosed locally

  2. The local O-6-Methylguanine-DNA Methyltransferase (MGMT) report determination should be available and should be uploaded to the electronic case report form (eCRF).

  3. Patient should have had a gross total or subtotal resection performed < 7 weeks prior to enrollment, documented at postoperative MRI. Patients who have had a biopsy only without resection are not eligible.

  4. Patient deemed suitable by the treating physician to receive the standard radiotherapy regimen in combination with temozolomide.

  5. Male or non-pregnant and non-lactating female and ≥ 18 to ≤ 70 years of age.

  6. Patient may have received and continue to receive corticosteroids, but must be on a stable or decreasing dose for at least 14 days prior to first dose of study treatment.

  7. Patient has not received prior chemotherapy or radiotherapy.

  8. Patient has adequate biological parameters as demonstrated by the following blood counts at Screening (obtained ≤ 14 days prior to enrollment) and at Baseline-Day 0: Absolute neutrophil count (ANC) ≥ 1.0 × 109/L; Platelet count ≥ 75,000/mm3 (75 × 109/L); Hemoglobin (Hgb) ≥ 9 g/dL without transfusion or growth factor support

  9. Patient has the following blood chemistry levels at Screening (obtained ≤ 14 days prior to enrollment) and at Baseline-Day 0:

    1. aspartate amino-transferase (AST)(SGOT), alanine transferase (ALT)(SGPT) ≤ 2.5 × upper limit of normal range (ULN). Total bilirubin ≤ 1.5 × ULN.
    2. Estimated creatinine clearance of > 60 mL/min (per Cockcroft -Gault formula)
  10. Patients with a QTC of ≤ 480 msec

  11. Patient has ECOG performance status of ≤ 2

  12. Patient has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent Form (ICF) prior to participation in any study-related activities.

Exclusion Criteria:

  1. Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for > 5 years
  2. Patients with a serious active infection (such as a wound infection requiring parenteral antibiotics) at the time of inclusion or other serious underlying medical conditions that would impair the ability of the patient to receive protocol treatment
  3. Patients with any condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol.
  4. Patients who have had treatment with any investigational cancer drug prior to the first dose of study treatment.
  5. Patient has experienced an increase of ECOG to > 2 between Screening and the time of first dose with azeliragon.
  6. Patients receiving CYP2C8 inhibitors
  7. Patient is unwilling or unable to comply with study procedures, including, but not limited to self-administration of oral medication.
  8. Patients with a gastrointestinal condition that could interfere with swallowing or absorption.
  9. Females of childbearing potential who are sexually active or males with female partners of childbearing potential, where either the female or the male is unwilling to use a highly effective method of contraception during the trial and for 6 months after the last administration of azeliragon.
  10. Patients with concurrent participation in another interventional clinical trial or use of another investigational agent within 14 days of starting azeliragon. Patients who are participating in non-interventional clinical trials (e.g., QOL, imaging, observational, follow-up studies, etc.) are eligible, regardless of the timing of participation.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Experimental arm

Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.

Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.

Azeliragon 5 mg once a day (loading initial dose for 6 days of 10 mg daily). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.

Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.

Azeliragon 10 mg once a day (loading initial dose for 6 days of 15 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.

Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.

Azeliragon 20 mg once a day (loading initial dose for 6 days of 30 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.

Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Recommended phase 2/3 dose
Prazo: Throughout the DLT observation period, approximately 28 days per patient

To assess the recommended phase 2/3 dose (RP2/3D) in mg/day of azeliragon in patients with newly diagnosed glioblastoma receiving concurrent radiation and temozolomide.

Dose limiting toxicities were defined as listed AEs, dose-reductions, treatment interruptions, or discontinuation occurring during the DLT period (28 days), which are attributable (definite, probable, possible) to azeliragon will be classified as a DLT. 6 patients must be treated at that dose level with ≤ 1 DLT observed

Throughout the DLT observation period, approximately 28 days per patient

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Incidence of adverse events (AEs)
Prazo: Throughout the study period, approximately 2 years per patient

Percentage of patients experiencing an adverse event

Throughout the study period, approximately 2 years per patient
Incidence of serious adverse events (SAEs)
Prazo: Throughout the study period, approximately 2 years per patient

Percentage of patients experiencing a serious adverse event

Throughout the study period, approximately 2 years per patient
Disease control rate (DCR)
Prazo: Throughout the study period, approximately 2 years per patient

Percentage of patients who experience a complete response, partial response or stable disease according to Response Assessment in Neuro-Oncology (RANO) criteria as their best response throughout the study

Throughout the study period, approximately 2 years per patient
Progression-free survival (PFS)
Prazo: Throughout the study period, approximately 2 years per patient

PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first

Throughout the study period, approximately 2 years per patient
Overall survival (OS)
Prazo: Throughout the study period, approximately 2 years per patient

Defined as the duration of time from start of treatment to time of death

Throughout the study period, approximately 2 years per patient
Patients with changes in the Eastern Cooperative Oncology Group (ECOG) performance status
Prazo: Throughout the study period, approximately 2 years per patient

Percentage of patients who experience a change in ECOG status through the study

Throughout the study period, approximately 2 years per patient
S100A9 expression levels
Prazo: Throughout the study period, approximately 2 years per patient in 3 occasions for each patient

Expression levels of the S100A9 molecular biomarker in blood samples from patients. Samples will be taken at baseline, Week 10 and after progression

Throughout the study period, approximately 2 years per patient in 3 occasions for each patient

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Cadeira de estudo: Juan Sepúlveda, Hospital Universitario 12 de Octubre

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

5 de setembro de 2023

Conclusão Primária (Real)

30 de abril de 2026

Conclusão do estudo (Real)

30 de abril de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

23 de novembro de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

23 de novembro de 2022

Primeira postagem (Real)

2 de dezembro de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

The individual participant data (IPD) anonymized could be shared upon request if the use is within the scope and protection level authorized by the patients by the signature of the informed consent

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever